We are developing target-activated covalent inhibitors
of protein SUMOylation to treat cancer patients.
MB231 cells with SUMO2 in red and DAPI (nuclei) in blue. courtesy of Jim D. Sutherland (CIC bioGUNE).
SumiQ Therapeutics was founded in January 2017 by UbiQ, a biotech company focused on the development and commercialization of research tools and small molecule drugs targeting the ubiquitin system and Mercachem, a privately owned leading European contract research organization offering innovative medicinal chemistry solutions.
UbiQ is a spin-out of the Netherlands Cancer Institute and based at the Amsterdam Science Park in the Netherlands. UbiQ has generated some of the first commercially available custom ubiquitinated peptides and now distributes a whole range of ubiquitin-related reagents worldwide. In addition to enabling drug discovery in the rapidly expanding ubiquitin research field, UbiQ is also actively developing small molecule inhibitors that target the ubiquitin system. UbiQ’s Triple E technology exploits a reactive group that specifically traps the E1, E2 and E3 ubiquitinating enzymes. By adding this ‘hook’ onto ubiquitin itself or onto a peptide or small molecule, it has now, for the first time, become possible to specifically monitor and block the activity of dozens of enzymes involved in protein ubiquitination. This technology was published in Nature Chemical Biology in May 2016. More information can be found on the company website www.ubiqbio.com.
SumiQ is a science-driven, focussed company. Our ambitious and enthusiastic team works in an informal setting, dedicated to developing a targeted therapy for cancer patients. When we have open positions, these are mentioned below. To apply for a position, please submit your CV and motivation letter to firstname.lastname@example.org with the position name in the title of your email.
ref: 20170327. closing date: 17 April 2017
At SumiQ we use rational design to develop mechanism-based covalent inhibitors of the enzymes involved in protein SUMOylation. Many Myc-driven tumours appear to critically depend on hyper-SUMOylation. SUMOylation inhibitors can revert the hyper-SUMOylation state and thus specifically kill Myc-driven tumours. SumiQ is now looking for an early career Researcher to join our Drug Discovery team to support this programme.
ref: 20170811. closing date: 1 October 2017
SumiQ is looking for a Life Sciences student for a biochemistry-oriented internship for at least 6 months.